<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02722733</url>
  </required_header>
  <id_info>
    <org_study_id>HL/NHLMobil-COI-01</org_study_id>
    <nct_id>NCT02722733</nct_id>
  </id_info>
  <brief_title>Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maria Sklodowska-Curie Institute - Oncology Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare safety and efficacy of stem cell mobilization using&#xD;
      G-CSF (filgrastim) alone vs. intermediate-dose cytosine arabinoside plus G-CSF in Hodgkin's&#xD;
      lymphoma and non-Hodgkin's lymphoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autologous hematopoietic stem cell transplantation (autoHSCT) is a standard treatment of&#xD;
      eligible patients suffering from Hodgkin's Lymphoma or non-Hodgkin's Lymphoma (HL, NHL).&#xD;
      AutoHSCT allows to further improve results of the therapy. Nowadays, 99% of the procedures&#xD;
      are performed using peripheral blood as a source of stem cells. Hence, the crucial point is&#xD;
      to harvest adequate number of stem cells allowing hematopoietic recovery. The number of 2 ×&#xD;
      10^6 CD34+ cells/kg is considered the minimal level in autoHSCT. There are two main&#xD;
      mobilization strategies being used: based on G-CSF alone or in combination with chemotherapy&#xD;
      (cyclophosphamide (CY) at dose range 1.6 g/m2 is mainly used in HL and NHL setting). However,&#xD;
      a proportion of patients (5-40%) fail to collect the minimum number of cells required. Novel&#xD;
      agents, like plerixafor, CXCR4 inhibitor, may enable effective CD34+ cell harvest in &quot;poor&#xD;
      mobilizers&quot;. Nevertheless, the optimal first-line and cost-effective protocol for&#xD;
      mobilization of hematopoietic stem cells has not been determined so far.&#xD;
&#xD;
      Randomized trials compare chemomobilization with the use of CY + G-CSF to G-CSF alone, which&#xD;
      had been conducted so far, did not demonstrate clear advantage of addition of CY to the&#xD;
      growth factor. Intermediate-dose cytosine arabinoside (AraC), 1.6 g/m2 plus filgrastim, has&#xD;
      been shown to produce very high efficacy as a first or second-line mobilization regimen in&#xD;
      patients with lymphoid malignancies. In a retrospective comparison, this strategy was&#xD;
      significantly more effective than CY + G-CSF. This suggest that the type of chemotherapy&#xD;
      agent added to G-CSF may play role in mobilization efficacy and that the combination of AraC&#xD;
      and G-CSF may be more effective than G-CSF used alone. The goal of current study is to verify&#xD;
      this hypothesis in randomized controlled trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• The proportion of patients with stem cell yield at least 2 × 10^6 CD34+ cells/kg in each treatment arm.</measure>
    <time_frame>After up to three leukaphereses (7-20 days after starting mobilization regimen).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak level of CD34+ cells in peripheral blood (cells/μl).</measure>
    <time_frame>7-20 days after starting mobilization regimen.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of harvested CD34+cells/kg.</measure>
    <time_frame>After up to three leukaphereses (7-20 days after starting mobilization regimen).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of leukaphereses needed to harvest target amount of stem cells.</measure>
    <time_frame>7-20 days after starting mobilization regimen.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of hematologic and non-hematologic complications.</measure>
    <time_frame>1 month after transplantation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of neutropenia &lt; 0.5 x10^9/L.</measure>
    <time_frame>1 month after transplantation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of blood transfusions needed.</measure>
    <time_frame>1 month after transplantation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay.</measure>
    <time_frame>1 month after transplantation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of neutrophil and platelet engraftment after autologous stem cel transplantation.</measure>
    <time_frame>1 month after transplantation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of thrombocytopenia &lt;50 x 10 ^9/L.</measure>
    <time_frame>1 month after transplantation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of antibiotics therapy.</measure>
    <time_frame>1 month after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>G-CSF (filgrastim)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.G-CSF at 10 μg/kg per day (divided into two doses every 12 hours) subcutaneously for up to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cytosine arabinoside + G-CSF (filgrastim)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cytosine arabinoside will be administered as a 2-hour i.v. infusion at a dose of 0.4 g/m2 twice daily on days 1 and 2 (total dose 1.6 g/m2).&#xD;
G-CSF 5-10 μg/kg per day (divided into two doses every 12 hours) will be started on day 5 subcutaneously and continued until last leukapheresis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF (filgrastim)</intervention_name>
    <arm_group_label>G-CSF (filgrastim)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytosine arabinoside with G-CSF (filgrastim)</intervention_name>
    <arm_group_label>Cytosine arabinoside + G-CSF (filgrastim)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hodgkin's lymphoma and non-Hodgkin's lymphoma patients considered eligible for&#xD;
             autologous stem cell transplantation procedure.&#xD;
&#xD;
          2. Must not have achieved complete remission after first line of therapy or must have&#xD;
             relapsed lymphoma.&#xD;
&#xD;
          3. Must have received at least two lines of therapy including four or more cycles.&#xD;
&#xD;
          4. Must have achieved a partial (PR) or complete remission (CR) .&#xD;
&#xD;
          5. Must be 18-65 years of age.&#xD;
&#xD;
          6. Must have World Health Organization performance status 0-1.&#xD;
&#xD;
          7. Time from administration or discontinuation of any chemotherapy agent must be at least&#xD;
             four weeks.&#xD;
&#xD;
          8. Hemoglobin level &gt; 8 g/dl, Absolute neutrophil count (ANC) &gt; 1.5 x 10^9/L, Platelet&#xD;
             count &gt;100 x 10^9/L.&#xD;
&#xD;
          9. Serum creatinine &lt; 1.5 x upper limit of normal (ULN), serum bilirubin &lt; 1.5 ULN, serum&#xD;
             aspartate transaminase (AST/SGOT) &lt; 2.5 x ULN, serum alanine transaminase (ALT/SGPT) &lt;&#xD;
             2.5 x ULN.&#xD;
&#xD;
         10. Negative human immunodeficiency virus (HIV) infection test.&#xD;
&#xD;
         11. Negative pregnancy test.&#xD;
&#xD;
         12. Must understand and voluntarily sign informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Failure of prior, first-line mobilization regimen.&#xD;
&#xD;
          2. Infiltration of central nervous system.&#xD;
&#xD;
          3. Bone marrow plasma cell infiltration of above 20%.&#xD;
&#xD;
          4. Administration of nitrosourea derivatives (Carmustine, Lomustine) within 4 weeks&#xD;
             before starting study treatment.&#xD;
&#xD;
          5. Administration of growth-factor other than G-CSF Administration of G-CSF within 14&#xD;
             days before starting study treatment.&#xD;
&#xD;
          6. Ongoing or active infection.&#xD;
&#xD;
          7. Coexisting neoplasm, other than Hodgkin's or non-Hodgkin's lymphoma.&#xD;
&#xD;
          8. Administration of radioimmunotherapy in past.&#xD;
&#xD;
          9. Pregnant or lactating females.&#xD;
&#xD;
         10. Patients treated with use of autologous or allogenic stem cell transplantation in the&#xD;
             past.&#xD;
&#xD;
         11. Positive human immunodeficiency virus (HIV) infection test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katarzyna Soska, MD</last_name>
    <phone>+48322788520</phone>
    <email>katarzyna.soska@io.gliwice.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch</name>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Giebel, Prof MD</last_name>
      <phone>+48322788523</phone>
      <email>ots@gliwice.io.pl</email>
    </contact>
    <investigator>
      <last_name>Katarzyna Soska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C, O'Connor C, Berkman E, Erban JK, Sprague KA, Miller KB, Schenkein DP. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood. 2001 Oct 1;98(7):2059-64.</citation>
    <PMID>11567990</PMID>
  </reference>
  <reference>
    <citation>Karanth M, Chakrabarti S, Lovell RA, Harvey C, Holder K, McConkey CC, McDonald D, Fegan CD, Milligan DW. A randomised study comparing peripheral blood progenitor mobilisation using intermediate-dose cyclophosphamide plus lenograstim with lenograstim alone. Bone Marrow Transplant. 2004 Sep;34(5):399-403.</citation>
    <PMID>15273706</PMID>
  </reference>
  <reference>
    <citation>Sheppard D, Bredeson C, Allan D, Tay J. Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2012 Aug;18(8):1191-203. doi: 10.1016/j.bbmt.2012.01.008. Epub 2012 Jan 16. Review.</citation>
    <PMID>22261379</PMID>
  </reference>
  <reference>
    <citation>Kruzel T, Sadus-Wojciechowska M, Najda J, Czerw T, Glowala-Kosinska M, Holowiecki J, Giebel S. Very high efficacy of intermediate-dose cytarabine in combination with G-CSF as a second-line mobilization of hematopoietic stem cells. Int J Hematol. 2012 Aug;96(2):287-9. doi: 10.1007/s12185-012-1135-5. Epub 2012 Jul 14.</citation>
    <PMID>22797877</PMID>
  </reference>
  <reference>
    <citation>Giebel S, Kruzel T, Czerw T, Sadus-Wojciechowska M, Najda J, Chmielowska E, Grosicki S, Jurczyszyn A, Pasiarski M, Nowara E, Glowala-Kosinka M, Chwieduk A, Mitrus I, Smagur A, Holowiecki J. Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers. Bone Marrow Transplant. 2013 Jul;48(7):915-21. doi: 10.1038/bmt.2012.269. Epub 2013 Jan 7.</citation>
    <PMID>23292239</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2016</study_first_posted>
  <last_update_submitted>March 24, 2016</last_update_submitted>
  <last_update_submitted_qc>March 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maria Sklodowska-Curie Institute - Oncology Center</investigator_affiliation>
    <investigator_full_name>Sebastian Giebel</investigator_full_name>
    <investigator_title>Prof., MD</investigator_title>
  </responsible_party>
  <keyword>Hodgkin's lymphoma</keyword>
  <keyword>Non-Hodgkin's lymphoma</keyword>
  <keyword>mobilization</keyword>
  <keyword>G-CSF</keyword>
  <keyword>filgrastim</keyword>
  <keyword>cytosine arabinoside</keyword>
  <keyword>autologous stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

